阿尔茨海默病中的免疫调节:从致病源到免疫疗法
Sahar Balkhi1, Anna Di Spirito1, Alessandro Poggi2
1Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Cells
|February 25, 2025
概括
本综述探讨了阿尔茨海默病 (AD) 的免疫疗法,重点是调节免疫反应,特别是微质活动,以清除粉样质斑块和团,可能减缓疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是老年人痴呆的主要原因.
- 病理学特征包括粉样β (Aβ) 斑块和来自高酸化的神经纤维状结 (NFT).
- 神经炎症和微质激活是AD进展的关键驱动因素.
研究的目的:
- 审查阿尔茨海默病免疫治疗的最新进展.
- 强调调节免疫反应的策略,重点关注微质的行为.
- 探索粉样蛋白清除和病理向的潜力.
主要方法:
- 关于阿尔茨海默病近期免疫治疗研究的文献综述.
- 对专注于微质调节的研究进行分析.
- 检查针对粉样β和病理学的方法.
主要成果:
- 免疫疗法在调节神经炎症方面表现有前途.
- 针对微质激活的策略可以增强粉样蛋白清除.
- 新兴疗法旨在通过免疫调节来减少病理.
结论:
- 免疫疗法为AD提供了潜在的治疗途径.
- 调节免疫反应,特别是微质活动,对于治疗疗效至关重要.
- 通过免疫疗法向粉样蛋白和蛋白病理可能会改变疾病的进展并改善患者的治疗结果.
相关概念视频
01:26Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
01:22Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149